Medtronic Q1 2025 Earnings Report
Key Takeaways
Medtronic reported Q1 worldwide revenue of $7.915 billion, an increase of 2.8% as reported and 5.3% on an organic basis. GAAP diluted earnings per share (EPS) were $0.80; non-GAAP diluted EPS of $1.23. The company raised its FY25 organic revenue growth guidance to 4.5% to 5% and diluted non-GAAP EPS guidance to the new range of $5.42 to $5.50.
Revenue of $7.9 billion, adjusted revenue of $8.0 billion, increased 2.8% as reported and 5.3% organic
GAAP diluted earnings per share (EPS) of $0.80; non-GAAP diluted EPS of $1.23
Company increases FY25 organic revenue growth and EPS guidance
Multiple franchises delivering, with growth acceleration in Cardiac Ablation Solutions and Neuromodulation and continued strength in Spine, Structural Heart, and Diabetes
Medtronic
Medtronic
Medtronic Revenue by Segment
Medtronic Revenue by Geographic Location
Forward Guidance
The company raised its FY25 organic revenue growth guidance to 4.5% to 5% versus the prior range of 4% to 5%. The company raised its FY25 diluted non-GAAP EPS guidance to the new range of $5.42 to $5.50 versus the prior $5.40 to $5.50. This includes an estimated -5% impact from foreign currency exchange based on recent rates, unchanged from the prior guidance.
Positive Outlook
- Expect to sustain growth from new product introductions
- Continue to make the investments to support those launches
- Deliver on our commitment to restore earnings power
Challenges Ahead
- Estimated -5% impact from foreign currency exchange based on recent rates
Revenue & Expenses
Visualization of income flow from segment revenue to net income